172 related articles for article (PubMed ID: 36808306)
21. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery.
Akiyama T; Ozaki K; Takano T; Yoneyama S; Kubota N; Okubo T; Ikegami R; Hoyano M; Yanagawa T; Inomata T
Intern Med; 2023 Nov; 62(22):3361-3365. PubMed ID: 37005262
[TBL] [Abstract][Full Text] [Related]
22. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
Nagendra L; Mahajan K; Gupta G; Dutta D
Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
[TBL] [Abstract][Full Text] [Related]
23. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
[TBL] [Abstract][Full Text] [Related]
24. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Canonico ME; Hess CN; Cannon CP
Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
[TBL] [Abstract][Full Text] [Related]
25. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
[TBL] [Abstract][Full Text] [Related]
27. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT).
Gargiulo P; Basile C; Cesaro A; Marzano F; Buonocore D; Asile G; Abbate V; Vicidomini F; Paolillo S; Spaccarotella CAM; Catalano A; Spirito G; Merlini PA; Maloberti A; Iannuzzo G; Ciccone MM; Zito AP; Paloscia L; D'Alleva A; Varbella F; Corleto A; Brunetti ND; Corbo MD; Calabrò P; Indolfi C; Perrone-Filardi P
Atherosclerosis; 2023 Feb; 366():32-39. PubMed ID: 36696749
[TBL] [Abstract][Full Text] [Related]
29. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
[TBL] [Abstract][Full Text] [Related]
30. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
[TBL] [Abstract][Full Text] [Related]
31. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease.
Itzhaki Ben Zadok O; Mager A; Leshem-Lev D; Lev E; Kornowski R; Eisen A
Cardiovasc Drugs Ther; 2022 Feb; 36(1):85-92. PubMed ID: 33394363
[TBL] [Abstract][Full Text] [Related]
33. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
[TBL] [Abstract][Full Text] [Related]
36. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
[No Abstract] [Full Text] [Related]
37. Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors.
Khatib R; Khan M; Barrowcliff A; Ikongo E; Burton C; Mansfield M; Hall A
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35393352
[TBL] [Abstract][Full Text] [Related]
38. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
39. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function.
Schremmer J; Busch L; Baasen S; Heinen Y; Sansone R; Heiss C; Kelm M; Stern M
Microvasc Res; 2023 Jul; 148():104513. PubMed ID: 36870561
[TBL] [Abstract][Full Text] [Related]
40. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Feng X; Berklein F; Rane PB; Habib M; Lin PJ
Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
